unit
state
million
peopl
chronic
obstruct
pulmonari
diseas
copd
copd
fourth
lead
caus
death
much
morbid
mortal
econom
impact
copd
due
acut
exacerb
exacerb
copd
associ
bacteri
viral
respiratori
tract
infect
well
exposur
airborn
pollut
two
studi
seemung
et
al
note
onethird
exacerb
copd
associ
respiratori
viru
infect
van
den
hoogen
et
al
report
discoveri
novel
paramyxoviru
human
metapneumoviru
hmpv
hmpv
sinc
identifi
global
similar
paramyxovirus
respiratori
syncyti
viru
rsv
parainfluenza
hmpv
appear
season
distribut
primarili
identifi
winter
earli
spring
north
america
hmpv
isol
children
adult
upper
lower
respiratori
tract
infect
associ
acut
onset
wheez
howev
full
spectrum
diseas
caus
hmpv
remain
determin
sought
determin
frequenc
hmpv
adult
hospit
due
exacerb
copd
decemb
may
patient
hospit
yalenew
hospit
urban
teach
hospit
provid
primari
tertiari
level
care
locat
new
connecticut
admiss
diagnosi
acut
exacerb
copd
identifi
nasopharyng
specimen
obtain
discret
clinician
care
patient
transport
laboratori
microtest
medium
remel
lenexa
ks
within
h
specimen
obtain
overnight
held
c
h
otherwis
specimen
process
laboratori
receipt
hmpv
test
perform
use
revers
transcriptaseepolymeras
chain
reaction
assay
rtepcr
primer
specif
hmpv
f
gene
previous
describ
rsv
influenza
b
adenoviru
identifi
cytospinenhanc
direct
immunofluoresc
assay
dfa
nasopharyng
specimen
requir
minimum
columnar
epitheli
cell
adequ
dfa
test
viral
cultur
perform
request
clinician
use
primari
rhesu
monkey
kidney
cell
cultur
accord
publish
method
techniqu
unabl
identifi
either
rhinoviru
coronavirus
patient
exclud
analysi
nasopharyng
specimen
unavail
obtain
within
first
day
hospit
inadequ
dfa
test
medic
record
review
obtain
inform
regard
patient
clinic
cours
acut
ill
past
medic
histori
patient
hospit
acut
exacerb
copd
studi
period
first
acut
exacerb
hospit
includ
sinc
durat
hmpv
shed
well
describ
hmpv
genotyp
determin
phylogenet
analysi
segment
hmpv
f
gene
correspond
nucleotid
hmpv
genbank
access
number
phylogenet
tree
deriv
maximum
likelihood
method
use
dnaml
phylip
version
dr
joseph
felsenstein
univers
washington
default
set
bootstrap
dataset
contain
permut
produc
bootseq
phylip
extend
majorityrul
consensu
tree
produc
use
consens
phylip
ttest
independ
sampl
fisher
exact
test
use
compar
continu
categor
variabl
respect
comparison
twotail
perform
use
spss
version
spss
chicago
il
p
valu
less
equal
consid
signific
ninetyf
percent
confid
interv
ci
calcul
use
clopperepearson
method
softwar
cytel
softwar
corp
cambridg
human
investig
committe
yale
univers
school
medicin
approv
research
decemb
may
patient
hospit
time
exacerb
copd
patient
met
enrol
criteria
twentyfour
patient
exclud
sinc
nasopharyng
specimen
obtain
first
five
hospit
day
patient
exclud
sinc
remain
nasopharyng
specimen
avail
hmpv
test
patient
exclud
sinc
nasopharyng
specimen
deem
inadequ
dfa
test
hmpv
identifi
ci
patient
rsv
ci
influenza
ci
parainfluenza
type
ci
patient
remain
neg
rsv
influenza
parainfluenza
adenoviru
hmpv
specimen
deem
inadequ
dfa
test
neg
hmpv
rtepcr
patient
identifi
one
viru
signific
differ
demograph
clinic
characterist
note
hospit
acut
exacerb
copd
patient
identifi
without
evid
hmpv
infect
howev
patient
hmpv
associ
acut
exacerb
frequent
febril
c
hospit
tabl
patient
hmpv
hospit
decemb
april
fig
note
chang
charact
cough
sputum
product
level
dyspnea
consist
accept
definit
acut
exacerb
copd
patient
receiv
support
care
broad
spectrum
antibiot
system
steroid
supplement
oxygen
hospit
three
six
patient
hmpv
evid
lower
respiratori
tract
infect
presenc
new
infiltr
chest
radiograph
patient
urin
legionella
antigen
test
perform
one
patient
patient
neg
gram
stain
cultur
perform
sputa
avail
three
patient
patient
fail
data
variabl
avail
enrol
patient
sd
standard
deviat
ns
signific
p
type
exacerb
defin
occurr
increas
dyspnea
sputum
product
cough
type
exacerb
defin
presenc
symptom
type
exacerb
defin
presenc
one
symptom
along
least
one
follow
upper
respiratori
tract
sign
symptom
preced
day
fever
increas
wheez
tachypnea
tachycardia
reveal
potenti
bacteri
pathogen
patient
identifi
hmpv
diagnos
suspect
acut
bacteri
respiratori
infect
period
hospit
among
acut
exacerb
copd
patient
without
evid
hmpv
sputum
gram
stain
cultur
perform
urin
legionella
test
obtain
two
patient
bacteri
diagnos
methicillinresist
staphylococcu
aureu
haemophilu
influenza
infect
made
one
patient
four
six
patient
hmpv
clinic
improv
initi
h
hospit
reflect
decreas
use
supplement
oxygen
two
patient
hmpvassoci
acut
exacerb
copd
requir
mechan
ventil
one
patient
receiv
noninvas
mask
ventil
clinic
improv
discharg
day
hospit
care
patient
histori
sever
copd
fev
ls
measur
year
prior
admiss
requir
invas
mechan
ventil
day
due
hypox
hypercapn
respiratori
failur
patient
slowli
improv
discharg
home
total
day
hospit
inadequ
pulmonari
function
test
data
avail
allow
reliabl
comparison
hmpv
nonhmpv
group
phylogenet
analysi
use
hmpv
f
gene
nucleotid
sequenc
show
exacerb
copd
associ
recogn
hmpv
genotyp
fig
sequenc
reveal
total
singl
nucleotid
substitut
site
within
nucleotid
f
gene
segment
six
hmpv
isol
site
locat
third
codon
posit
one
codon
contain
substitut
first
third
posit
neither
polymorph
encod
amino
acid
chang
deduc
amino
acid
sequenc
homolog
b
genotyp
f
gene
segment
respiratori
virus
respons
signific
proport
exacerb
copd
major
caus
disabl
popul
recent
investig
identifi
hmpv
patient
experienc
exacerb
copd
microbi
pathogen
could
identifi
howev
recent
publish
studi
found
evid
hmpv
infect
among
acut
respiratori
ill
experienc
patient
copd
nearli
studi
period
studi
use
rtepcr
identifi
hmpv
remain
unknown
whether
tempor
andor
geograph
differ
circul
hmpv
may
led
differ
find
studi
perform
winter
earli
spring
hmpv
typic
detect
incid
rsv
influenza
also
typic
peak
winter
declin
earli
spring
north
america
thu
frequenc
exacerb
associ
hmpv
rsv
influenza
like
greatest
studi
period
found
similar
rate
observ
investig
unabl
success
determin
patient
receiv
influenza
vaccin
season
remain
unclear
whether
hmpv
significantli
affect
patient
copd
season
temper
climat
identifi
specif
demograph
clinic
characterist
distinguish
hmpv
nonhmpv
acut
exacerb
copd
howev
studi
limit
power
identifi
characterist
rtepcr
use
identifi
hmpv
studi
becom
standard
diagnost
test
hmpv
hmpv
difficult
cultur
dfa
test
current
avail
commerci
rsv
influenza
parainfluenza
adenoviru
detect
cytospinenhanc
dfa
tissu
cultur
method
routin
employ
clinic
virolog
laboratori
laboratori
cytospin
enhanc
dfa
shown
sensit
similar
convent
cell
cultur
identif
influenza
parainfluenza
rsv
compar
realtim
rtepcr
detect
influenza
hmpv
infect
observ
patient
like
repres
reinfect
sinc
shown
person
seroposit
hmpv
year
age
rsv
parainfluenza
durat
degre
protect
immun
may
wane
time
shown
hmpv
isol
segreg
two
distinct
genotyp
phylogenet
analysi
therefor
possibl
infect
one
hmpv
genotyp
may
confer
complet
protect
immun
hmpv
strain
previou
report
describ
patient
infect
genet
distinct
hmpv
strain
sequenti
year
howev
issu
remain
unresolv
suggest
coinfect
hmpv
rsv
may
potenti
explain
varianc
sever
rsv
ill
children
hmpv
coinfect
may
play
role
pathogenesi
sever
acut
respiratori
syndrom
sar
studi
identifi
patient
exacerb
copd
coinfect
rsv
hmpv
despit
focus
patient
sever
ill
result
hospit
investig
includ
hospit
patient
signific
proport
exacerb
copd
either
requir
hospit
brought
medic
attent
shown
mani
adult
patient
hmpv
infect
experi
mild
moder
respiratori
ill
often
lead
medic
evalu
infrequ
result
hospit
therefor
possibl
hmpv
may
greater
impact
qualiti
life
healthcar
util
patient
copd
suggest
find
durat
hmpv
carriag
frequenc
asymptomat
carriag
optim
period
diagnost
test
well
character
studi
base
review
medic
record
document
mani
often
differ
healthcar
provid
due
signific
interobserv
variabl
quantit
durat
onset
ill
diagnost
test
concern
rais
regard
durat
viral
nucleic
acid
carriag
henc
specif
pcr
base
diagnost
test
patient
copd
howev
hmpv
rare
identifi
patient
lack
sign
symptom
acut
respiratori
ill
william
et
al
identifi
hmpv
children
without
evid
respiratori
tract
infect
furthermor
recent
studi
beckham
et
al
fail
identifi
hmpv
infect
group
copd
patient
experienc
acut
respiratori
ill
suggest
identif
hmpv
patient
experienc
exacerb
copd
like
repres
etiolog
exacerb
rather
unrel
epiphenomena
studi
shown
hmpv
frequent
associ
exacerb
copd
result
hospit
prospect
populationbas
studi
necessari
defin
impact
hmpv
patient
copd
epidemiolog
hmpv
method
prevent
hmpv
infect
potenti
role
copathogen
respiratori
pathogen
hmpv
shown
signific
impact
patient
copd
suggest
studi
develop
hmpv
vaccin
may
merit
consider
